Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synchroneuron, a privately-held biopharmaceutical company, has concluded $6m Series A financing from Morningside Technology Ventures to further develop a treatment for tardive dyskinesia (TD).
Subscribe to our email newsletter
Synchroneuron co-founder and CSO Fogel said they aim to bring relief to millions of patients with TD and other movement disorders by developing novel therapies.
The company plans to commence Phase 1 clinical trials this year.
Synchroneuron is engaged in developing a new treatment for movement disorders, utilizing a drug with simultaneous effects on excitatory and inhibitory neurotransmission.
Morningside is a diversified investment group engaged primarily in private equity and venture capital investments.